Company:  ORAMED PHARMACEUTICALS IN ... (ORMP)
Form Type:  10-K
Filing Date:  11/27/2013 
CIK:  0001176309 
Address:  HI-TECH PARK 2/4 GIVAT-RAM
PO BOX 39098
 
City, State, Zip:  JERUSALEM,  91390 
Telephone:  011 972-2-566-0001 
Fiscal Year:  08/31 
Last Trade
Last Trade: 
$7.40  
Change: 
-0.42 (-5.37%)  
Trade Time: 
Oct 30  
Market Cap: 
$73.67M
Description of Business
We are a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Oral insulin: We are seeking to revolutionize the treatment of diabetes through our proprietary flagship product, an orally ingestible insulin capsule (ORMD0801) currently in non-U.S. Food and Drug Administration, or FDA, approved Phase 2 clinical trials. Our technology allows insulin to travel from the gastrointestinal tract via the portal vein to the bloodstream, revolutionizing the manner in which insulin is delivered. It enables its passage in a more physiological manner than current delivery methods of insulin. Our technology is a platform that has the potential to deliver medications and vaccines orally that today can only be delivered via injection.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS.
      ITEM 1A. RISK FACTORS.
      ITEM 1B. UNRESOLVED STAFF COMMENTS.
      ITEM 2. PROPERTIES.
      ITEM 3. LEGAL PROCEEDINGS.
      ITEM 4. MINE SAFETY DISCLOSURES.
    PART II
      ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED FINANCIAL DATA.
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES.
      ITEM 9B. OTHER INFORMATION.
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
        NAME AND TITLE
      ITEM 11. EXECUTIVE COMPENSATION.
        COMPENSATION TABLE
        OPTIONS AGGREGATE
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
        BENEFICIAL OWNERS
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND ...
      ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.
    PART IV
      ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    BALANCE SHEET
    STOCKHOLDERS EQUITY
    STOCKHOLDERS EQUITY
    STOCKHOLDERS EQUITY
    CASH FLOW
    NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:
      INCOME STATEMENT
      NOTE 17 - SUBSEQUENT EVENTS:
    SIGNATURES
  EXHIBIT 3.1
    CERTIFICATE OF INCORPORATION
  EXHIBIT 21.1
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 23.2
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE ...
  EXHIBIT 31.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE ...
  EXHIBIT 32.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
  EXHIBIT 32.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER
BROKERAGE PARTNERS